Category: Medical Research
![Gb Sciences' First-in-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study at the University of Lethbridge](https://cdn.nwe.io/files/x/ae/79/979e040c668e3af85786da0f5262.jpg)
The Parkinson's disease market is expected to grow to $12.8 billion by 2028.
![Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform](https://cdn.nwe.io/files/x/9a/99/ba32f10d9b5c1778d257eb1e435e.jpg)
Gb Sciences' innovative approach harnesses the power of plant-based treatments as simplified mixtures that target dangerous hyperinflammatory responses to viral infections.
![Gb Sciences Co-Publishes Study Demonstrating Anti-Inflammatory Properties of Cannabis Ingredients](https://cdn.nwe.io/files/x/1d/40/63c32e3c26de828d6275327bc524.jpg)
As published in the journal Food and Chemical Toxicology, the biopharmaceutical drug development firm's sponsored research used co-cultured human, primary immune cells as a model to evaluate the ability of selected Cannabis constituents to decrease inflammation.
![TODAY: Gb Sciences' President Demonstrates Benefits of AI-Enabled Drug Discovery Engine for Novel Plant-Inspired Pharmaceuticals at 10th Annual Drug Discovery Strategic Summit](https://cdn.nwe.io/files/x/b5/2d/4877bef2c0711a852d101f526114.jpg)
At the Annual Summit, Dr. Andrea Small-Howard is presenting a Keynote Address that includes data from case studies demonstrating the utility of Gb Sciences' proprietary PhAROS drug discovery platform.
![Gb Sciences' Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study](https://cdn.nwe.io/files/x/bb/c3/a621d6db9e47c2c12d23ea10b575.jpg)
Gb Sciences' anxiety formulations were previously identified using the company's AI-driven PhAROS™ platform, and they have now been evaluated using preclinical zebrafish models of stress at the National Research Council of Canada.
![Gb Sciences Co-Publishes Study Demonstrating Efficacy of Its Proprietary Cannabinoid Mixtures for the Treatment of Parkinson's Disease](https://cdn.nwe.io/files/x/3a/6e/3a0910e45df78c904e348a8048e9.jpg)
As published in Frontiers in Pharmacology, the biopharmaceutical drug development firm's sponsored research has identified and validated cannabinoid ratio-controlled, Minimum Essential Mixtures (MEM) for the treatment of Parkinson's disease symptoms
![TODAY: Gb Sciences Describes Drug Development Progress in Pharma's Almanac Journal Article](https://cdn.nwe.io/files/x/6f/35/67f3714f135f0cb925f77936e91e.jpg)
Gb Sciences is focusing considerable resources on bringing its lead Parkinson's disease formulations to the clinic with promising results; plus, new data validating the efficacy of their novel anxiety formulations and demonstrating the improved stability of their oral nanoparticle-encapsulated chronic pain formulations add value to their drug development pipeline.
![Gb Sciences is Leading Digital Transformation in Biopharma Industry Through Its Novel AI-Accelerated Drug Discovery Platform—PhAROS™](https://cdn.nwe.io/files/x/85/ff/b79e4a7caf3d8b1f364362b4da2f.jpg)
As digitization becomes a necessity in the life sciences industry, Gb Sciences proves it's already ahead of the curve with its own revolutionary technology.
![Gb Sciences Leads Digital Transformation in Biopharma Industry Through Its Novel AI-Accelerated Drug Discovery Platform—PhAROS™](https://cdn.nwe.io/files/x/85/ff/b79e4a7caf3d8b1f364362b4da2f.jpg)
As digitization becomes a necessity in the life sciences industry, Gb Sciences proves it's already ahead of the curve with its own revolutionary technology.
![Gb Sciences to Begin Dosage Study for Its Novel Parkinson's Disease Formulations at the University of Lethbridge](https://cdn.nwe.io/files/x/d5/2d/05cedffb8afba383e441f24c16cf.jpg)
Biopharmaceutical research company's plant-inspired formulations entering final stages before first-in-human clinical trials
![Gb Sciences Targets COVID-19 Treatment as Omicron Variant Arrives](https://cdn.nwe.io/files/x/fb/e1/63ec6e82b7b6993a3737cb559e34.jpg)
Biopharmaceutical research company leverages positive data on its cannabinoid-containing mixtures to develop new cytokine release syndrome therapies
![Gb Sciences Presenting COVID-Related Cytokine Release Syndrome Results at H.C. Wainwright's 23rd Annual Global Investment Conference](https://cdn.nwe.io/files/x/01/32/981dd6bd19c0cd1d0aeb7828b1f9.jpg)
Highlighting Gb Sciences' Development of Plant-Inspired Therapies for COVID-related Cytokine Release Syndrome, Chronic Pain, and Parkinson's Disease during the Healthcare & Biotech Track starting Monday, September 13.